Selective inhibition of low-affinity memory CD8(+) T cells by corticosteroids

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · see citing works

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357 · see citing works

Elements of cancer immunity and the cancer–immune set point

Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352 · see citing works

Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation

Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294 · see citing works

Molecular and cellular insights into T cell exhaustion

Wherry, E. J., & Kurachi, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3862 · Cited by 4,652 · see citing works

Enhancement of Antitumor Immunity by CTLA-4 Blockade

Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955 · see citing works

<i>Batf3</i> Deficiency Reveals a Critical Role for CD8α ⁺ Dendritic Cells in Cytotoxic T Cell Immunity

Hildner, K., Edelson, B. T., Purtha, W. E., Diamond, M., Matsushita, H., Kohyama, M., Calderon, B., Schraml, B. U., Unanue, E. R., Diamond, M. S., et al. (2008) · Science · doi:10.1126/science.1164206 · Cited by 2,081 · see citing works

Inflammation Directs Memory Precursor and Short-Lived Effector CD8+ T Cell Fates via the Graded Expression of T-bet Transcription Factor

Joshi, N. S., Cui, W., Chandele, A., Lee, H. K., Urso, D. R., Hagman, J., Gapin, L., & Kaech, S. M. (2007) · Immunity · doi:10.1016/j.immuni.2007.07.010 · Cited by 1,861 · see citing works

T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition

Hui, E., Cheung, J., Zhu, J., Su, X., Taylor, M. J., Wallweber, H. A., Sasmal, D. K., Huang, J., Kim, J. M., Mellman, I., et al. (2017) · Science · doi:10.1126/science.aaf1292 · Cited by 1,689 · see citing works

Enhancing CD8 T-cell memory by modulating fatty acid metabolism

Pearce, E. L., Walsh, M. C., Cejas, P. J., Harms, G. M., Shen, H., Wang, L.-S., Jones, R. G., & Choi, Y. (2009) · Nature · doi:10.1038/nature08097 · Cited by 1,559 · see citing works

Mitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development

van der Windt, G. J. W., Everts, B., Chang, C.-H., Curtis, J. D., Freitas, T. C., Amiel, E., Pearce, E. J., & Pearce, E. L. (2012) · Immunity · doi:10.1016/j.immuni.2011.12.007 · Cited by 1,540 · see citing works

Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity

Curiel, T. J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K. L., Daniel, B., Zimmermann, M. C., et al. (2003) · Nature Medicine · doi:10.1038/nm863 · Cited by 1,314 · see citing works

The future of cancer treatment: immunomodulation, CARs and combination immunotherapy

Khalil, D. N., Smith, E. L., Brentjens, R. J., & Wolchok, J. D. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.25 · Cited by 1,151 · see citing works

Regulatory T cells exert checks and balances on self tolerance and autoimmunity

Wing, K., & Sakaguchi, S. (2009) · Nature Immunology · doi:10.1038/ni.1818 · Cited by 1,110 · see citing works

Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center

Horvat, T. Z., Adel, N. G., Dang, T.-O., Momtaz, P., Postow, M. A., Callahan, M. K., Carvajal, R. D., Dickson, M. A., D'Angelo, S. P., Woo, K. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.60.8448 · Cited by 1,064 · see citing works

Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors

Pitt, J. M., Vétizou, M., Daillère, R., Roberti, M. P., Yamazaki, T., Routy, B., Lepage, P., Boneca, I. G., Chamaillard, M., Kroemer, G., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.06.001 · Cited by 1,040 · see citing works

Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent

Kamphorst, A. O., Wieland, A., Nasti, T., Yang, S., Zhang, R., Barber, D. L., Konieczny, B. T., Daugherty, C. Z., Koenig, L., Yu, K., et al. (2017) · Science · doi:10.1126/science.aaf0683 · Cited by 1,015 · see citing works

Targeting neoantigens to augment antitumour immunity

Yarchoan, M., Johnson, B. A., Lutz, E. R., Laheru, D. A., & Jaffee, E. M. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.154 · Cited by 997 · see citing works

Glucocorticoid resistance in inflammatory diseases

Barnes, P. J., & Adcock, I. M. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60326-3 · Cited by 983 · see citing works

CD28 Costimulation: From Mechanism to Therapy

Esensten, J. H., Helou, Y. A., Chopra, G., Weiss, A., & Bluestone, J. A. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.020 · Cited by 937 · cited 1× · see citing works

Glucocorticoids in T Cell Development and Function

Ashwell, J. D., Lu, F. W. M., & Vacchio, M. S. (2000) · Annual Review of Immunology · doi:10.1146/annurev.immunol.18.1.309 · Cited by 777 · see citing works

Complete but curtailed T-cell response to very low-affinity antigen

Zehn, D., Lee, S. Y., & Bevan, M. J. (2009) · Nature · doi:10.1038/nature07657 · Cited by 697 · see citing works

T cell defined tumor antigens

den Eynde, B. J. V., & van der Bruggen, P. (1997) · Current Opinion in Immunology · doi:10.1016/s0952-7915(97)80050-7 · Cited by 629 · see citing works

Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression

Lin, H., Wei, S., Hurt, E. M., Green, M. D., Zhao, L., Vatan, L., Szeliga, W., Herbst, R., Harms, P. W., Fecher, L. A., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96113 · Cited by 580 · see citing works

Targeting T Cell Co-receptors for Cancer Therapy

Callahan, M. K., Postow, M. A., & Wolchok, J. D. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.023 · Cited by 468 · see citing works

Is autoimmunity the Achilles' heel of cancer immunotherapy?

June, C. H., Warshauer, J. T., & Bluestone, J. A. (2017) · Nature Medicine · doi:10.1038/nm.4321 · Cited by 445 · see citing works

Etomoxir Actions on Regulatory and Memory T Cells Are Independent of Cpt1a-Mediated Fatty Acid Oxidation

Raud, B., Roy, D. G., Divakaruni, A. S., Tarasenko, T. N., Franke, R., Ma, E. H., Samborska, B., Hsieh, W. Y., Wong, A., Stüve, P., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.06.002 · Cited by 389 · see citing works

Eradication of Established Tumors by CD8+ T Cell Adoptive Immunotherapy

Hanson, H. L., Donermeyer, D. L., Ikeda, H., White, J. M., Shankaran, V., Old, L. J., Shiku, H., Schreiber, R. D., & Allen, P. M. (2000) · Immunity · doi:10.1016/s1074-7613(00)00026-1 · Cited by 358 · see citing works

Chromatin immunoprecipitation (ChIP) scanning identifies primary glucocorticoid receptor target genes

Wang, J.-C., Derynck, M. K., Nonaka, D. F., Khodabakhsh, D. B., Haqq, C., & Yamamoto, K. R. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407008101 · Cited by 320 · see citing works

Intercellular Adhesion Molecule-1-Dependent Stable Interactions between T Cells and Dendritic Cells Determine CD8+ T Cell Memory

Scholer, A., Hugues, S., Boissonnas, A., Fetler, L., & Amigorena, S. (2008) · Immunity · doi:10.1016/j.immuni.2007.12.016 · Cited by 255 · see citing works

Glucocorticoid Receptor-Dependent Gene Regulatory Networks

Le, P. P., Friedman, J. R., Schug, J., Brestelli, J. E., Parker, J. B., Bochkis, I. M., & Kaestner, K. H. (2005) · PLoS Genetics · doi:10.1371/journal.pgen.0010016 · Cited by 250 · see citing works

The role of colon anaerobes in the metabolism of bile acids and steroids, and its relation to colon cancer

Hill, M. J. (2006) · Cancer · doi:10.1002/1097-0142(197512)36:6 · Cited by 195 · see citing works

In vivo antigen delivery by aSalmonella typhimurium type III secretion system for therapeutic cancer vaccines

Nishikawa, H. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28045 · Cited by 183 · see citing works

Glucocorticoid signaling: a nongenomic mechanism for T-cell immunosuppression

Löwenberg, M., Verhaar, A. P., BRINK, G. R. V. D., & Hommes, D. W. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.02.001 · Cited by 154 · see citing works

Glucocorticoid Receptor (GR)-Associated SMRT Binding to C/EBPβ TAD and Nrf2 Neh4/5: Role of SMRT Recruited to GR in GSTA2 Gene Repression

Ki, S. H., Cho, I. J., Choi, D. W., & Kim, S. G. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.10.4150-4165.2005 · Cited by 145 · see citing works

Two Distinct Mechanisms of Augmented Antitumor Activity by Modulation of Immunostimulatory/Inhibitory Signals

Mitsui, J., Nishikawa, H., Muraoka, D., Wang, L., Noguchi, T., Sato, E., Kondo, S., Allison, J. P., Sakaguchi, S., Old, L. J., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3243 · Cited by 135 · see citing works

Establishment of Antitumor Memory in Humans Using in Vitro–Educated CD8 + T Cells

Butler, M. O., Friedlander, P. A., Milstein, M. I., Mooney, M. M., Metzler, G., Murray, A. P., Tanaka, M., Berezovskaya, A., Imataki, O., Drury, L., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002207 · Cited by 107 · see citing works

Pembrolizumab-Induced Encephalopathy: A Review of Neurological Toxicities with Immune Checkpoint Inhibitors

Feng, S., Coward, J. I. G., McCaffrey, E., Coucher, J., Kalokerinos, P. N., & O'Byrne, K. J. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.08.007 · Cited by 106 · see citing works

Low-Affinity T Cells Are Programmed to Maintain Normal Primary Responses but Are Impaired in Their Recall to Low-Affinity Ligands

Knudson, K. M., Goplen, N., Cunningham, C. A., Daniëls, M. A., & Teixeiro, E. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.07.008 · Cited by 70 · see citing works

CCAAT/Enhancer Binding Protein-β Is a Transcriptional Regulator of Peroxisome-Proliferator-Activated Receptor-γ Coactivator-1α in the Regenerating Liver

Wang, H., Peiris, T. H., Mowery, A., Lay, J. E. L., Gao, Y., & Greenbaum, L. E. (2008) · Molecular Endocrinology · doi:10.1210/me.2007-0388 · Cited by 52 · see citing works

Diversity and collaboration for effective immunotherapy

Palucka, K., & Banchereau, J. (2016) · Nature Medicine · doi:10.1038/nm.4249 · Cited by 11 · see citing works

Immunogenicity and toxicity of AAV gene therapy

Ertl, H. C. J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.975803 · Cited by 402 · see citing works

Tumors induce de novo steroid biosynthesis in T cells to evade immunity

Mahata, B., Pramanik, J., van der Weyden, L., Polański, K., Kar, G., Riedel, A., Chen, X. X., Fonseca, N. A., Kundu, K., Campos, L. S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17339-6 · Cited by 329 · see citing works

EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors

Kostine, M., Finckh, A., Bingham, C. O., Visser, K., Leipe, J., Schulze‐Koops, H., Choy, E., Benesova, K., Radstake, T. R. D. J., Cope, A. P., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-217139 · Cited by 301 · see citing works

Endogenous Glucocorticoid Signaling Regulates CD8+ T Cell Differentiation and Development of Dysfunction in the Tumor Microenvironment

Acharya, N., Madi, A., Zhang, H., Klapholz, M., Escobar, G., Dulberg, S., Christian, E., Ferreira, M., Dixon, K. O., Fell, G. G., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.08.005 · Cited by 252 · see citing works

Glucocorticoids in T cell development, differentiation and function

Taves, M. D., & Ashwell, J. D. (2020) · Nature reviews. Immunology · doi:10.1038/s41577-020-00464-0 · Cited by 235 · see citing works

Anti-Inflammatory Drugs Remodel the Tumor Immune Environment to Enhance Immune Checkpoint Blockade Efficacy

Pelly, V. S., Moeini, A., Roelofsen, L. M., Bonavita, E., Bell, C. R., Hutton, C., Blanco‐Gómez, A., Banyard, A., Bromley, C. P., Flanagan, E., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1815 · Cited by 226 · see citing works

Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: Review of the literature and personalized risk-based prevention strategy

Haanen, J., Ernstoff, M. S., Wang, Y., Menzies, A. M., Puzanov, I., Grivas, P., Larkin, J., Peters, S., Thompson, J. A., & Obeid, M. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.285 · Cited by 222 · see citing works

Metabolism in tumor microenvironment: Implications for cancer immunotherapy

Shi, R., Tang, Y., & Miao, H. (2020) · MedComm · doi:10.1002/mco2.6 · Cited by 198 · see citing works

Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma

Iorgulescu, J. B., Gokhale, P. C., Speranza, M. C., Eschle, B. K., Poitras, M. J., Wilkens, M. K., Soroko, K. M., Chhoeu, C., Knott, A., Gao, Y., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2291 · Cited by 191 · see citing works

Insights from a 30-year journey: function, regulation and therapeutic modulation of PD1

Chamoto, K., Yaguchi, T., Tajima, M., & Honjo, T. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-023-00867-9 · Cited by 185 · see citing works

New insights into the cell- and tissue-specificity of glucocorticoid actions

Quatrini, L., & Ugolini, S. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00526-2 · Cited by 171 · see citing works

Corticosteroids and Cancer Immunotherapy

Goodman, R. S., Johnson, D. B., & Balko, J. M. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3181 · Cited by 160 · see citing works

T cell exhaustion in malignant gliomas

Watowich, M., Gilbert, M. R., & Larion, M. (2023) · Trends in cancer · doi:10.1016/j.trecan.2022.12.008 · Cited by 130 · see citing works

Neuro-immune crosstalk in cancer: mechanisms and therapeutic implications

Pu, T., Sun, J., Ren, G., & Li, H. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02241-8 · Cited by 140 · see citing works

Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance

Verheijden, R. J., van Eijs, M. J. M., May, A. M., van Wijk, F., & Suijkerbuijk, K. P. M. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00380-1 · Cited by 123 · see citing works

The cancer-immune dialogue in the context of stress

Ma, Y., & Kroemer, G. (2023) · Nature reviews. Immunology · doi:10.1038/s41577-023-00949-8 · Cited by 110 · see citing works

Challenges in glioblastoma immunotherapy: mechanisms of resistance and therapeutic approaches to overcome them

Habashy, K. J., Mansour, R., Moussalem, C., Sawaya, R., & Massaad, M. J. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01864-w · Cited by 95 · see citing works

Glucocorticoids and the cytokines IL-12, IL-15, and IL-18 present in the tumor microenvironment induce PD-1 expression on human natural killer cells

Quatrini, L., Vacca, P., Tumino, N., Besi, F., Pace, A. L. D., Scordamaglia, F., Martini, S., Munari, E., Mingari, M. C., Ugolini, S., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.04.044 · Cited by 90 · see citing works

Aging-associated and CD4 T-cell–dependent ectopic CXCL13 activation predisposes to anti–PD-1 therapy-induced adverse events

Tsukamoto, H., Komohara, Y., Tomita, Y., Miura, Y., Motoshima, T., Imamura, K., Kimura, T., Ikeda, T., Fujiwara, Y., Yano, H., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2205378119 · Cited by 80 · see citing works

Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal

Isoyama, S., Mori, S., Sugiyama, D., Kojima, Y., Tada, Y., Shitara, K., Hinohara, K., Dan, S., & Nishikawa, H. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002279 · Cited by 76 · see citing works

Glucocorticoid regulation of cancer development and progression

Khadka, S., Druffner, S. R., Duncan, B. C., & Busada, J. T. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1161768 · Cited by 75 · see citing works

The glucocorticoids prednisone and dexamethasone differentially modulate T cell function in response to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade

Okoye, I., Xu, L., Walker, J. W. T., & Elahi, S. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02555-2 · Cited by 56 · see citing works

Longitudinal Analysis of Human Memory T-Cell Response According to the Severity of Illness up to 8 Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Kang, C. K., Kim, M., Lee, S., Kim, G., Choe, P. G., Park, W. B., Kim, N. J., Lee, C., Kim, I. S., Jung, K., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab159 · Cited by 56 · see citing works

Survival Among Veterans Receiving Steroids for Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy

Buren, I. V., Madison, C. J., Kohn, A. D., Berry, E., Kulkarni, R. P., & Thompson, R. F. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.40695 · Cited by 54 · see citing works

Control of T Cell Metabolism by Cytokines and Hormones

Bishop, E. L., Gudgeon, N. H., & Dimeloe, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.653605 · Cited by 53 · see citing works

The effects of glucocorticoids and immunosuppressants on cancer outcomes in checkpoint inhibitor therapy

Bruera, S., & Suarez-Almazor, M. E. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.928390 · Cited by 49 · see citing works

MicroRNA-21-Enriched Exosomes as Epigenetic Regulators in Melanomagenesis and Melanoma Progression: The Impact of Western Lifestyle Factors

Melnik, B. C., John, S. M., Carrera‐Bastos, P., & Schmitz, G. (2020) · Cancers · doi:10.3390/cancers12082111 · Cited by 43 · see citing works

Reconsidering Dexamethasone for Antiemesis when Combining Chemotherapy and Immunotherapy

Janowitz, T., Kleeman, S., & Vonderheide, R. H. (2021) · The Oncologist · doi:10.1002/onco.13680 · Cited by 42 · see citing works

Adult immuno-oncology: using past failures to inform the future

Rahman, M., Sawyer, W. G., Lindhorst, S., Deleyrolle, L. P., Harrison, J. K., Karachi, A., Dastmalchi, F., Flores‐Toro, J., Mitchell, D. A., Lim, M. K., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa116 · Cited by 33 · see citing works

Antimetastatic defense by CD8+ T cells

de Lara, P. T., Castañón, H., Sterpi, M., & van den Broek, M. F. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.10.006 · Cited by 32 · see citing works

Dexamethasone premedication suppresses vaccine-induced immune responses against cancer

Vormehr, M., Lehar, S. M., Kranz, L. M., Tähtinen, S., Oei, Y. A., Javinal, V., Delamarre, L., Walzer, K. C., Diken, M., Kreiter, S., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1758004 · Cited by 28 · see citing works

Impact of immune-related adverse events on the therapeutic efficacy of pembrolizumab in urothelial carcinoma: a multicenter retrospective study using time-dependent analysis

Kawai, T., Taguchi, S., Nakagawa, T., Kamei, J., Nakamura, Y., Obinata, D., Yamaguchi, K., Kaneko, T., Kakutani, S., Tokunaga, M., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003965 · Cited by 29 · see citing works

Immune Checkpoint Inhibitor-related Pancreatitis: A Case Series, Review of the Literature and an Expert Opinion

Kramer, S., van Hee, K., Blokzijl, H., van der Heide, F., & Visschedijk, M. C. (2023) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000472 · Cited by 29 · see citing works

Immunotherapy drives mesenchymal tumor cell state shift and TME immune response in glioblastoma patients

Hendriksen, J. D., Locallo, A., Maarup, S. B., Debnath, O., Ishaque, N., Hasselbalch, B., Skjøth‐Rasmussen, J., Yde, C. W., Poulsen, H. S., Lassen, U., et al. (2024) · Neuro-Oncology · doi:10.1093/neuonc/noae085 · Cited by 28 · see citing works

Mineralocorticoid receptor antagonists and glucocorticoids differentially affect skeletal muscle inflammation and pathology in muscular dystrophy

Howard, Z. M., Gomatam, C. K., Rabolli, C. P., Lowe, J., Piepho, A. B., Bansal, S. S., Accornero, F., & Rafael‐Fortney, J. A. (2022) · JCI Insight · doi:10.1172/jci.insight.159875 · Cited by 27 · see citing works

SimBu : bias-aware simulation of bulk RNA-seq data with variable cell-type composition

Dietrich, A., Sturm, G., Merotto, L., Marini, F., Finotello, F., & List, M. (2022) · Bioinformatics · doi:10.1093/bioinformatics/btac499 · Cited by 27 · see citing works

Steroid-refractory immune checkpoint inhibitor (ICI) hepatitis and ICI rechallenge: A systematic review and meta-analysis

Hwang, S. Y., Hsieh, P., & Zhang, W. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000525 · Cited by 24 · see citing works

The immunopathogenesis of idiopathic nephrotic syndrome: a narrative review of the literature

Kitsou, K. S., Askiti, V., Mitsioni, A., & Spoulou, V. I. (2022) · European Journal of Pediatrics · doi:10.1007/s00431-021-04357-9 · Cited by 23 · see citing works

Immune‐related adverse events in non‐small cell lung cancer: Occurrence, mechanisms and therapeutic strategies

Lin, X., Xie, M., Yao, J., Ma, X., Lin, Q., Zhang, X., Song, J., Bao, X., Zhang, X., Zhang, Y., et al. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1613 · Cited by 24 · see citing works

Prognostic impact of proton pump inhibitors for immunotherapy in advanced urothelial carcinoma

Okuyama, Y., Hatakeyama, S., Numakura, K., Narita, T., Tanaka, T. D., Miura, Y., Sasaki, D., Noro, D., Tokui, N., Okamoto, T., et al. (2021) · BJUI Compass · doi:10.1002/bco2.118 · Cited by 22 · see citing works

Effect of Systemic Steroid Use for Immune-Related Adverse Events in Patients with Non-Small Cell Lung Cancer Receiving PD-1 Blockade Drugs

Mouri, A., Kaira, K., Yamaguchi, O., Hashimoto, K., Miura, Y., Shiono, A., Shinomiya, S., Imai, H., Kobayashi, K., & Kagamu, H. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10163744 · Cited by 22 · see citing works

Glucocorticoid imprints a low glucose metabolism onto CD8 T cells and induces the persistent suppression of the immune response

Konishi, A., Suzuki, J., Kuwahara, M., Matsumoto, A., Nomura, S., Soga, T., Yorozuya, T., & Yamashita, M. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.12.050 · Cited by 21 · see citing works

Better Late Than Never: The Impact of Steroidal Treatment on the Outcome of Melanoma Patients Treated with Immunotherapy

Bar-Hai, N., Ben‐Betzalel, G., Stoff, R., Grynberg, S., Schachter, J., Shapira‐Frommer, R., & Asher, N. (2023) · Cancers · doi:10.3390/cancers15113041 · Cited by 20 · see citing works

Discontinuation of immune checkpoint inhibitors for reasons other than disease progression and the impact on relapse and survival of advanced melanoma patients. A systematic review and meta-analysis

Lallas, K., Chatziioannou, E., Durak, D., Frey, G., Serna-­Higuita, L. M., Rasch, M.-L., Kyrgidis, Α., Timotheadou, E. T., Apalla, Z., Leiter, U., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1524945 · Cited by 19 · see citing works

Musculoskeletal immune-related adverse events in 927 patients treated with immune checkpoint inhibitors for solid cancer

Melia, A., Fockens, E., Sfumato, P., Zemmour, C., Madroszyk, A., Lafforgue, P., & Pham, T. (2022) · Joint Bone Spine · doi:10.1016/j.jbspin.2022.105457 · Cited by 18 · see citing works

Steroid hormone regulation of immune responses in cancer

Anderson, A. C., & Acharya, N. (2022) · Immunometabolism · doi:10.1097/in9.0000000000000012 · Cited by 18 · see citing works

Genetic control of the dynamic transcriptional response to immune stimuli and glucocorticoids at single-cell resolutionPreprint

Resztak, J., Wei, J., Zilioli, S., Sendler, E. D., Alazizi, A., Mair-Meijers, H. E., Wu, P., Wen, X., Slatcher, R. B., Zhou, X., et al. (2023) · Genome Research · doi:10.1101/gr.276765.122 · Cited by 19 · see citing works

CAR T cells and T cells phenotype and function are impacted by glucocorticoid exposure with different magnitude

Poiret, T., Vikberg, S., Schoutrop, E., Mattsson, J., & Magalhaes, I. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05063-4 · Cited by 17 · see citing works

Anti-VEGF Antibody Protects against Alveolar Exudate Leakage Caused by Vascular Hyperpermeability, Resulting in Mitigation of Pneumonitis Induced by Immunotherapy

Iwai, T., Sugimoto, M., Patel, H., Yorozu, K., Kurasawa, M., & Kondoh, O. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0031 · Cited by 16 · see citing works

Coactivation of innate immune suppressive cells induces acquired resistance against combined TLR agonism and PD-1 blockade

Nishinakamura, H., Shinya, S., Irie, T., Sakihama, S., Naito, T., Watanabe, K., Sugiyama, D., Tamiya, M., Yoshida, T., Hase, T., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adk3160 · Cited by 16 · see citing works

Fulminant Type 1 Diabetes Mellitus Developed about Half a Year after Discontinuation of Immune Checkpoint Inhibitor Combination Therapy with Nivolumab and Ipilimumab: A Case Report

Yaura, K., Sakurai, K., Niitsuma, S., Sato, R., Takahashi, K., & Arihara, Z. (2021) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.254.253 · Cited by 16 · see citing works

Functionally Masked Antibody to Uncouple Immune-Related Toxicities in Checkpoint Blockade Cancer Therapy

Song, S. H., Ghosh, T., You, D. G., Joo, H., Lee, J., Lee, J., Kim, C. H., Jeon, J., Shin, S., & Park, J. H. (2023) · ACS Nano · doi:10.1021/acsnano.2c12532 · Cited by 15 · see citing works

IL-2 complex recovers steroid-induced inhibition in immunochemotherapy for head and neck cancer

Kono, M., Yamaki, H., Komatsuda, H., Kumai, T., Hayashi, R., Wakisaka, R., Sato, R., Ohara, K., Kishibe, K., Takahara, M., et al. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101358 · Cited by 13 · see citing works

The glucocorticoid receptor modulator relacorilant reverses the immunosuppressive effects of cortisol

Greenstein, A. E., & Hunt, H. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110312 · Cited by 13 · see citing works

Role of FoxP3 + Regulatory T Cells in Modulating Immune Responses to Adeno-Associated Virus Gene Therapy

Muñoz-Melero, M., & Biswas, M. (2024) · Human Gene Therapy · doi:10.1089/hum.2023.227 · Cited by 13 · see citing works

The impact of concomitant medications on treatment outcomes in patients with cancer receiving immune checkpoint inhibitors

Stone, S., McPherson, J. P., Kulkarni, R. P., & Young, A. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00890-z · Cited by 13 · see citing works

Molecular methods to study protein trafficking between organs

Kreissl, F. K., Banki, M. A., & Droujinine, I. A. (2022) · Proteomics · doi:10.1002/pmic.202100331 · Cited by 11 · see citing works

Immune checkpoint inhibitors for progressive multifocal leukoencephalopathy: Identifying relevant outcome factors

Lambert, N., Moussaoui, M. E., & Maquet, P. (2021) · European Journal of Neurology · doi:10.1111/ene.15021 · Cited by 12 · see citing works

Association of immune-related adverse events with immune checkpoint inhibitor efficacy: real or imaginary?

Haratani, K., Hayashi, H., & Nakagawa, K. (2020) · BMC Medicine · doi:10.1186/s12916-020-01583-0 · Cited by 12 · see citing works

Leveraging epigenetic biomarker proxies for precision medicinePreprint

Carreras-Gallo, N., Chen, Q., Balagué-Dobón, L., Aparicio, A., Giosan, I. M., Dargham, R., Phelps, D., Guo, T., Melnikas, M., Mendez, K. M., et al. (2024) · medRxiv · doi:10.1101/2024.12.06.24318612 · Cited by 11 · see citing works

Immune checkpoint inhibitor rechallenge after immune-related adverse events: a retrospective study from VigiBase update in 2024 looking for emergent safety signals

L'Orphelin, J. ‐., Silva, A. D., Cabon, J., Alexandre, J., & Dolladille, C. (2024) · BMJ Open · doi:10.1136/bmjopen-2024-091708 · Cited by 11 · see citing works

Effect of Systemic Corticosteroid Therapy on the Efficacy and Safety of Nivolumab in the Treatment of Non-Small-Cell Lung Cancer

Umehara, K., Yama, K., Goto, K., Wakamoto, A., Hatsuyama, T., Honjo, O., Saikai, T., 藤田, 昭., & Sato, H. (2021) · Cancer Control · doi:10.1177/1073274820985790 · Cited by 11 · see citing works

Chinese expert consensus recommendations for the administration of immune checkpoint inhibitors to special cancer patient populations

Wang, J., Zhang, B., Peng, L., Liu, X., Sun, J., Su, C., Wang, H., Zhao, Z., Si, L., Duan, J., et al. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231187205 · Cited by 11 · see citing works

Exploiting immunometabolism and T cell function for solid organ transplantation

Allocco, J., & Alegre, M. (2020) · Cellular Immunology · doi:10.1016/j.cellimm.2020.104068 · Cited by 11 · see citing works

Compromise or not? A case report of successful treatment of pembrolizumab‐induced hepatitis in a patient with non‐small cell lung cancer with low‐dose methylprednisolone and bicyclol

Liu, Y., Zhang, J., Yin, Z., Zhu, X., Xue, L., & Cao, B. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13463 · Cited by 11 · see citing works

Immune checkpoint inhibitors-associated cranial nerves involvement: a systematic literature review on 136 patients

Pichon, S., Aigrain, P., Lacombe, C., Lemarchant, B., Ledoult, E., Koether, V., Leurs, A., Zebian, G., Launay, D., Gachet, B., et al. (2024) · Journal of Neurology · doi:10.1007/s00415-024-12660-2 · Cited by 10 · see citing works

T-Cell Metabolism in Graft Versus Host Disease

Karl, F., Hudecek, M., Berberich‐Siebelt, F., Mackensen, A., & Mougiakakos, D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.760008 · Cited by 10 · see citing works

Atezolizumab Treatment for Progressive Multifocal Leukoencephalopathy

Lambert, N., Dauby, S., Dive, D., Sadzot, B., & Maquet, P. (2021) · Emerging infectious diseases · doi:10.3201/eid2801.204809 · Cited by 10 · see citing works

Synergistic effect between denosumab and immune checkpoint inhibitors (ICI)? A retrospective study of 268 patients with ICI and bone metastases

Mabrut, E., Mainbourg, S., Péron, J., Maillet, D., Dalle, S., Fontaine-Delaruelle, C., Grolleau, E., Clézardin, P., Bonnelye, E., Confavreux, C., et al. (2024) · Journal of bone oncology · doi:10.1016/j.jbo.2024.100634 · Cited by 9 · see citing works

Uncovering the immune mechanisms underlying the emergence of immunotherapy-induced pneumonitis in lung cancer patients

Lin, X., Li, C. C., Deng, J., Wu, Y., Xie, B., Bao, J., Mo, W., Zhong, C., Deng, H., Pan, Q., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-66509-x · Cited by 9 · see citing works

Dexamethasone and OLT1177 Cooperate in the Reduction of Melanoma Growth by Inhibiting STAT3 Functions

Dinarello, A., Mills, T., Tengesdal, I. W., Powers, N. E., Azam, T., & Dinarello, C. A. (2023) · Cells · doi:10.3390/cells12020294 · Cited by 9 · see citing works

Glucocorticoid-mediated Suppression of Effector Programming Assists the Memory Transition of Virus-specific CD8+ T Cells

Tehseen, A., Kumar, D., Dubey, A., Sarkar, R., Singh, S., & Sehrawat, S. (2024) · The Journal of Immunology · doi:10.4049/jimmunol.2300513 · Cited by 9 · see citing works

Precision immunomodulation: Understanding and harnessing cytokine pathways to treat and prevent immune-related adverse events (irAEs)

Hadfield, M. J., Merkin, R. D., Rouhani, S. J., & Reynolds, K. L. (2025) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2025.101625 · Cited by 8 · see citing works

Optimal timing of steroid initiation in response to CTLA-4 antibody in metastatic cancer: A mathematical model

Siewe, N., & Friedman, A. (2022) · PLoS ONE · doi:10.1371/journal.pone.0277248 · Cited by 8 · see citing works

The Binary Model of Chronic Diseases Applied to COVID-19

Elkoshi, Z. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.716084 · Cited by 8 · see citing works

Genetic control of the dynamic transcriptional response to immune stimuli and glucocorticoids at single cell resolutionPreprint

Resztak, J., Wei, J., Zilioli, S., Sendler, E. D., Alazizi, A., Mair-Meijers, H. E., Wu, P., Wen, X., Slatcher, R. B., Zhou, X., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.09.30.462672 · Cited by 8 · see citing works

Impact of Non-steroidal Anti-inflammatory Drugs, Glucocorticoids, and Disease-Modifying Anti-Rheumatic Drugs on Cancer Response to Immune Checkpoint Inhibitor Therapy

Chan, K. K., & Bass, A. R. (2024) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2024.02.007 · Cited by 7 · see citing works

Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancer

Haratani, K., Nakamura, A., Mamesaya, N., Sawa, K., Shiraishi, Y., Saito, R., Tanizaki, J., Tamura, Y., Hata, A., Tsuruno, K., et al. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02662-2 · Cited by 7 · see citing works

Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population

Prinzi, F. L., Salani, F., Camera, S., Rizzato, M. D., Saborowski, A. L., Antonuzzo, L., Rossari, F., Satake, T., Peeters, F., Pressiani, T., et al. (2025) · International Journal of Cancer · doi:10.1002/ijc.70009 · Cited by 6 · see citing works

T Cell Energy Metabolism Is a Target of Glucocorticoids in Mice, Healthy Humans, and MS Patients

Meyer-Heemsoth, L., Mitschke, K., Bier, J., Schütz, K., Villunger, A., Legler, T. J., Weber, M. S., Lühder, F., & Reichardt, H. M. (2023) · Cells · doi:10.3390/cells12030450 · Cited by 6 · see citing works

Actinomycotic Sinomaxillary Infection in a COVID-19 Patient: A Case Report and Review of the Literature

Moaddabi, A., Cernera, M., Armogida, N. G., Soltani, P., & Spagnuolo, G. (2023) · Journal of Investigative Medicine High Impact Case Reports · doi:10.1177/23247096231217823 · Cited by 5 · see citing works

Eclipsing Toxicity, Enhancing Efficacy: Clofazimine’s Vanguard in the Realm of Anti-PD-1 and CTLA-4 Immunotherapy

Tan, R., Zhao, J., & Shubhra, Q. T. H. (2024) · Research · doi:10.34133/research.0419 · Cited by 5 · see citing works

Revisiting prophylactic corticosteroids to mitigate severe immune-related adverse events in hepatocellular carcinoma

Shen, Y., Pinato, D. J., Liu, T., Lu, L., Chuang, C.-H., Chen, P.-Y., Shao, Y., Lin, Z., & Cheng, A. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2026.01.009 · Cited by 4 · see citing works

Coadministration of a Clinically Relevant Dexamethasone Dosage With Ablative Radiation Therapy Reduces Peripheral Lymphocytes But Does Not Alter In Vivo Intratumoral Lymphocyte Phenotype or Inhibit Efficacy of Radiation Therapy in a Murine Colorectal Tumor Model

Battaglia, N. G., Uccello, T. P., Hughson, A., Garrett-Larsen, J., Caldon, J. J., Qiu, H., Gerber, S. A., & Lord, E. M. (2021) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2021.04.021 · Cited by 4 · see citing works

Corticosteroid premedication on anti-tumor effect of immune checkpoint blockade in murine hepatocellular carcinoma models

Shen, Y., Chang, N.-W., Yeh, C.-P., Lin, W.-Y., Wei, M., Ou, D., Hsu, C., & Cheng, A. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009704 · Cited by 5 · see citing works

Cyclophilin A Plays Potential Roles in a Rat Model of Asthma and Suppression of Immune Response

Chen, C.-T., Shan, C.-X., Ran, J., Yin, L.-M., Li, H., Wang, Y., Xu, Y., Jing-lei, G., Shi, Y.-L., Chen, Y., et al. (2021) · Journal of Asthma and Allergy · doi:10.2147/jaa.s308938 · Cited by 4 · see citing works

Hormonal rewiring of immunity during dietary restriction ensures host defense and systemic glucose conservation

Menezes-Silva, L., Jeong, M., Carr, C., Schneider, R. M., Pires, S., Codo, A. C., Uddin, J., Grier, A., Longman, R., Câmara, N. O. S., et al. (2026) · Immunity · doi:10.1016/j.immuni.2026.01.003 · Cited by 3 · see citing works

Cytotoxic Molecules as Potential Biomarkers for Active and Inactive Systemic Lupus Erythematosus

Santana-Sánchez, P., Ramírez-Pérez, A. A., Alberti‐Minutti, P., Gajón, J. A., Bonifaz, L. C., Sánchez-Escobar, N., Legorreta-Haquet, M. V., Chávez-Sanchéz, L., & Chávez-Rueda, A. K. (2025) · Biomedicines · doi:10.3390/biomedicines13071559 · Cited by 3 · see citing works

Association between glucocorticoid discontinuation and incidence of infection in older adults with rheumatoid arthritis: A retrospective cohort study

Goto, Y., Nagafuchi, H., Kaga, Y., & Kawahata, K. (2023) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.14851 · Cited by 3 · see citing works

Evaluation of immune checkpoint inhibitors for colorectal cancer: A network meta‑analysis

Tzang, C.-C., Lee, Y.-W., Lin, W., Lin, L., Kang, Y.-F., Lin, T.-Y., Wu, W., & Chang, K. C. (2024) · Oncology Letters · doi:10.3892/ol.2024.14702 · Cited by 3 · see citing works

Pan-cancer analysis reveals the value of FDX1 as a novel biomarker in the prognosis and immunotherapy in human tumorsPreprint

Zhang, Q., Liu, N., Wu, D., Xu, Z., Wang, Y., & Wang, P. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.06.22.497145 · Cited by 3 · see citing works

Favorable Prognosis in Patients With Multiple Myeloma and Lenalidomide‐Induced Skin Rash: A Multicenter Retrospective Study

Nakamura, A., Kimura, Y., Tanaka, Y., Tsuchimoto, D., Naruse, A., Kanematsu, T., Takeuchi, K., Tomita, N., Miyazawa, K., Fukuoka, T., et al. (2024) · European Journal Of Haematology · doi:10.1111/ejh.14333 · Cited by 2 · see citing works

Effect of steroid therapy on survival in patients with metastatic solid tumors experiencing immune-related adverse events

Acar, C., Şahin, G., Yüksel, H. Ç., Açar, F. P., Karaca, B. S., & Göker, E. (2026) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2026.2614710 · Cited by 2 · see citing works

Tumor‑associated glucocorticoid inhibition by mifepristone reduces polymorphonuclear myeloid‑derived suppressor cells and promotes antitumor immunity in triple‑negative breast cancer‑bearing mice

Kobayashi, M., Konno, C., SHIMIZU, A., Kobayashi, M., & Tatsuya, H. O. R. I. (2026) · Oncology Reports · doi:10.3892/or.2026.9065 · Cited by 2 · see citing works

Immediate and Gradual Withdrawal of Immunosuppression After Kidney Graft Loss Lead to Similar Outcomes

Nabil, A., Congy‐Jolivet, N., Darres, A., Guy, P., Marion, O., Milhès, J., Prudhomme, T., Kamar, N., & Bello, A. D. (2026) · Transplant International · doi:10.3389/ti.2026.15642 · Cited by 2 · see citing works

Prednisolone modulates CD8⁺ and regulatory T-cell activity to dampen response to immune checkpoint inhibitor therapy in melanoma

Brown, J. R., Pedersen, B., Long, G. V., Maher, N. G., Lim, S. Y., Rizos, H., & Shklovskaya, E. (2026) · OncoImmunology · doi:10.1080/2162402x.2026.2643494 · Cited by 2 · see citing works

Establishment of immune suppression by cancer cells in the tumor microenvironment

Nishikawa, H. (2024) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.100.005 · Cited by 2 · see citing works

Effect of Corticosteroids on Long-Term Humoral and Memory T-Cell Responses in Follow-Up Visit of Hospitalized Patients With COVID-19

Wang, Y., Guo, L., Fan, G., Yang, H., Zhang, Q., Wang, W., Ren, X., Zhang, H., Wang, G., Zhang, X., et al. (2024) · CHEST Journal · doi:10.1016/j.chest.2024.02.044 · Cited by 2 · see citing works

The Mitigating Effect of Combined Glucocorticoids with Immune Checkpoint Inhibitors on Lymphocyte Activation Gene‐3 and Programmed Death‐1 Expression

Gertel, S., Polachek, A., Furer, V., Dovrat, T. O., Avaky, C., Broyde, A., Nochimovitz, H., & Elkayam, O. (2025) · European Journal of Immunology · doi:10.1002/eji.70033 · Cited by 2 · see citing works

Later is better: Corticosteroids selectively suppress early memory T cells

Kulkarni, R. P. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz3711 · Cited by 2 · see citing works

Later is better: Corticosteroids selectively suppress early memory T cells

Kulkarni, R. P. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz3711 · Cited by 2 · see citing works

Abstract 5615: Effects of corticosteroids on tumor immunity induced by anti-CTLA-4 mAb therapy in a mouse model

Maeda, Y., Kato, T., Wang, L., Muraoka, D., Sato, E., Wolchok, J. D., Old, L. J., Shiku, H., & Nishikawa, H. (2010) · Cancer Research · doi:10.1158/1538-7445.am10-5615

Corticosteroid premedication on anti-tumor effect of immune checkpoint blockade in murine hepatocellular carcinoma models

Shen, Y., Chang, N.-W., Yeh, C.-P., Lin, W.-Y., Wei, M., Ou, D., Hsu, C., & Cheng, A. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009704 · Cited by 5 · see citing works

Prednisolone modulates CD8⁺ and regulatory T-cell activity to dampen response to immune checkpoint inhibitor therapy in melanoma

Brown, J. R., Pedersen, B., Long, G. V., Maher, N. G., Lim, S. Y., Rizos, H., & Shklovskaya, E. (2026) · OncoImmunology · doi:10.1080/2162402x.2026.2643494 · Cited by 2 · see citing works

Differential effects of corticosteroids and anti‐TNF on tumor‐specific immune responses: implications for the management of irAEs

Draghi, A., Borch, T. H., Radic, H. D., Chamberlain, C. A., Gokuldass, A., Svane, I. M., & Donia, M. (2018) · International Journal of Cancer · doi:10.1002/ijc.32080 · Cited by 51 · see citing works